Technical Analysis for ASND - Ascendis Pharma A/S

Grade Last Price % Change Price Change
grade A 128.96 3.46% 4.31
ASND closed up 3.46 percent on Friday, May 24, 2019, on 67 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Earnings due: May 30

*** please verify all earnings dates ***
1 Watcher
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical ASND trend table...

Date Alert Name Type % Chg
Stochastic Sell Signal Bearish 0.00%
Overbought Stochastic Strength 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 3.46%
Cup with Handle Other 3.46%
Overbought Stochastic Strength 3.46%
Cup with Handle Other 1.90%
Overbought Stochastic Strength 1.90%
Up 3 Days in a Row Strength 1.90%
Cup with Handle Other 2.06%
Inside Day Range Contraction 2.06%

Older signals for ASND ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Read My Charts!
Configure default chart indicators
Basic chart:

Profile
Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies to treat unmet medical needs. It is developing TransCon human growth hormone that has completed Phase II clinical trials in adults to treat growth hormone deficiency (GHD) and other indications, as well as in Phase II studies in children for treating GHD; and TransCon Treprostinil for the treatment of pulmonary arterial hypertension, a life-threatening disease characterized by elevated blood pressure in the pulmonary arteries. The company is also developing TransCon Insulin for the treatment of diabetes; and TransCon Ranibizumab, a compound to support ranibizumab injection. It has strategic collaborations with Sanofi, Genentech, and United Therapeutics Corporation. The company was founded in 2006 and is headquartered in Hellerup, Denmark.
Biotechnology Life Sciences Disease Diabetes Hormones Pulmonary Arterial Hypertension Peptide Hormones Treatment Of Diabetes Genentech Recombinant Proteins Breakthrough Therapy Treprostinil
Is ASND a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
May 20 Ascendis Pharma's TransCon shows favorable safety profile in late-stage study
May 20 Ascendis Pharma A/S Announces Preliminary Data from Single Arm Phase 3 fliGHt Trial Demonstrated TransCon™ hGH was Safe and Well-Tolerated in Pediatric Subjects Previously Treated with Daily Growth Hormone
May 16 Ascendis Pharma A/S Announces First Quarter 2019 Financial Results and Business Update Conference Call on May 30
May 7 Ascendis Pharma A/S Announces Participation in the Bank of America Merrill Lynch 2019 Healthcare Conference
May 7 Wyndham Hotels & Resorts, Inc. (WH): 2019 Sohn Conference New York Recap
May 6 What You Must Know About Ascendis Pharma A/S's (NASDAQ:ASND) Financial Health
Apr 29 The Prognosis For Ascendis Pharma
Apr 29 Did Hedge Funds Drop The Ball On Ascendis Pharma A/S (ASND) ?
Apr 27 Glenview Capital Management’s Stock Pitches At 2018 Sohn Conference
Apr 24 Ascendis Pharma A/S Announces Presentations Related to Rare Disease Endocrinology Pipeline at Upcoming Medical Conferences
See more ASND news...
Indicators
Indicator Value
52 Week High 131.755
52 Week Low 53.205
Average Volume 283,280
200-Day Moving Average 82.1982
50-Day Moving Average 118.4028
20-Day Moving Average 121.5715
10-Day Moving Average 123.54
Average True Range 4.3866
ADX 16.21
+DI 25.7405
-DI 15.5566
Chandelier Exit (Long, 3 ATRs ) 116.4802
Chandelier Exit (Short, 3 ATRs ) 119.4398
Upper Bollinger Band 130.1115
Lower Bollinger Band 113.0315
Percent B (%b) 0.93
BandWidth 14.049345
MACD Line 3.2152
MACD Signal Line 2.7535
MACD Histogram 0.4617
Fundamentals Value
Market Cap 4.19 Billion
Num Shares 32.5 Million
EPS -3.61
Price-to-Earnings (P/E) Ratio -35.72
Price-to-Sales 288.07
Price-to-Book 6.90
PEG Ratio -0.32
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 136.57
Resistance 3 (R3) 135.95 132.79 135.30
Resistance 2 (R2) 132.79 130.86 133.10 134.87
Resistance 1 (R1) 130.88 129.66 131.84 131.50 134.45
Pivot Point 127.72 127.72 128.20 128.03 127.72
Support 1 (S1) 125.81 125.79 126.77 126.43 123.47
Support 2 (S2) 122.65 124.59 122.96 123.05
Support 3 (S3) 120.74 122.65 122.62
Support 4 (S4) 121.36